VF
EGRX

Virtu Financial’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Virtu Financial’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-12,890
Closed -$48K – 2273
2024
Q3 		$48K Buy
+12,890
New +$61.5K ﹤0.01% 1018
2018
Q1 		– Sell
-5,870
Closed -$314K – 2748
2017
Q4 		$314K Buy
+5,870
New +$327K 0.02% 1225

Other funds holding EGRX

XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
SLG
Stanley-Laman Group Berwyn, Pennsylvania $814M AUM 40.24% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
AIC
Archer Investment Corporation Carmel, Indiana $469M AUM 19.1% 1-Year Est. Return
Credit Agricole
Credit Agricole Montrouge Cedex, France $38.1B AUM
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

Virtu Financial's EGRX Position: Q4 2024 in Review

Virtu Financial sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q4 2024, closing a stake of 12,890 shares — an estimated $48K sold.

Virtu Financial first reported a position in EGRX in Q4 2017 and held it in 2 quarters. The position peaked at $314K in Q4 2017. 9 funds tracked by Wall St. Rank hold EGRX as of Q4 2024.

  • Virtu Financial reported no remaining Eagle Pharmaceuticals, Inc. position as of Q4 2024 after selling out during the quarter.
  • Virtu Financial sold 12,890 Eagle Pharmaceuticals, Inc. shares in Q4 2024, an estimated $48K.
  • Virtu Financial first reported a position in Eagle Pharmaceuticals, Inc. in Q4 2017 and held it in 2 quarters.
  • Virtu Financial's Eagle Pharmaceuticals, Inc. position peaked at $314K in Q4 2017.
  • 9 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q4 2024.

Based on Virtu Financial's 13F filing for Q4 2024, filed 11 Feb 2025.